Abstract
Insulin access and affordability affect the well-being of millions of Americans. In the 116th Congress (2019-2020), seven bipartisan bills were introduced to address this issue. In this article, the authors group the seven bills into five categories (enhancing price transparency, limiting cost-sharing, changing biosimilar regulations, certifying prices, and permitting importation), summarize the main content of these bills, and discuss their implications. Understanding the bipartisan insulin pricing policy proposals can facilitate the development of a feasible legislative agenda to improve insulin access and affordability.